Page 11 - கிஂட்ரிட் உயிர் அறிவியல் இன்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Kindred Biosciences Unveils Positive Results from its Long-Acting Interleukin-31 Antibody PK Study

Share this article Share this article SAN FRANCISCO, April 20, 2021 /PRNewswire/ Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today unveiled positive results in a new long-acting interleukin (IL)-31 antibody program (KIND-039) that integrates the company s novel half-life extension technology. Results from the pharmacokinetic study of the molecule demonstrate that the fully caninized, high-affinity antibody has up to a three-fold longer half-life compared to tirnovetmab. This extended half-life is expected to allow for up to three-fold longer interval between dosing. One of the main unmet needs in the canine dermatitis market is reduced dosing frequency and increased convenience. With these exciting results, we believe our new long-acting IL-31 antibody program has the potential to become a best-in-class therapeutic and the treatment of choice in the large and growing dermatitis market, said KindredBi

Katja buhrerRichard chinExchange commissionDechra pharmaceuticalsKindred biosciences incDrug administrationUnited states department of agriculture centerKindred biosciencesChief executive officerSecurities litigation reform actAnnual reportQuarterly reportsUnited states departmentAgriculture centerVeterinary biologicsரிச்சர்ட் கன்னம்

Veterinary Medicine Market Will Hit Big Revenues In Future | Merck Animal Health, Ceva Sante Animale, Vetoquinol S A , Zoetis – KSU

Veterinary Medicine market’ Report @ Global Veterinary Medicine Market is valued approximately USD 27.19 billion in 2019 and is anticipated to grow with a healthy growth rate of more than 7.4 % over the forecast period 2020-2027. Veterinary Medicine is a product which is used to treat various medical conditions in animals. Veterinary Medicine is used for treating injuries and illness in animals. Also, they include vaccines for animals, to build immunity in animals against various infectious diseases such as equine influenza (EIV) and parainfluenza 3-respiratory syncytial. Further, increase in number of pet owners and livestock population and their demand around the world has led the adoption of Veterinary Medicine across the forecast period. For Instance: as per the company source, in 2019, Ceva collaborated with ProBioGen Ag for manufacturing vectorized poultry vaccines with ProBioGen’s proprietary AGE1.CR technology. However, lack of veterinary infrastructure facilities in

United statesHong kongUnited kingdomCzech republicNew zealandSouth koreaRepublic ofSouth africaSaudi arabiaCeva sante animaleBoehringer ingelheim gmbAsia pacificMerck animal healthResearch methodologyKindred biosciences incKey consulting companies advisors

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), (ACIU) - The Daily Biotech Pulse: Fulgent Nabs CDC Contract, Enzo Rallies, Solid Biosciences Releases Gene Therapy Data, Moderna Begins Pediatric Vaccine Study

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), (ACIU) - The Daily Biotech Pulse: Fulgent Nabs CDC Contract, Enzo Rallies, Solid Biosciences Releases Gene Therapy Data, Moderna Begins Pediatric Vaccine Study
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

South africaUnited statesDavid lowranceWarburg pincusGary huggDavid ramsayJoseph maccrackenElazar rabbaniUs centers for diseaseSotera healthNational institute of allergyKindred biosciences incCuris incSystems incRubius therapeutics incBiohaven pharmaceutical holding company ltd

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), AcelRx Pharmaceuticals, Inc (NASDAQ:ACRX) - Week Ahead In Biotech (March 14-20): Update On Fibrogen-AstraZeneca s Anemia Drug, Earnings and Presentations

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), AcelRx Pharmaceuticals, Inc (NASDAQ:ACRX) - Week Ahead In Biotech (March 14-20): Update On Fibrogen-AstraZeneca s Anemia Drug, Earnings and Presentations
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

Strongbridge biopharmaEli lillyThermogenesis holdings incBiotechnology corporationRubius therapeutics incCatalyst pharmaceuticals incBridgebio pharma incAcelrx pharmaceuticals incPrometheus biosciences incMuscular dystrophy associationOrganogenesis holdings incGalmed pharmaceuticals ltdFibrogen incAmphastar pharmaceuticals incUrogen pharma ltdInternational conference on alzheimer

Kindred Biosciences to Present at Barclays Global Healthcare Conference and H C Wainwright Global Life Sciences Conference

An archived version of the above webcasts will be available for 30 days on the KindredBio website. About Kindred Biosciences Kindred Biosciences is a biopharmaceutical company developing innovative biologics focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company s strategy is to identify targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated targets for dogs and cats. KindredBio has a deep pipeline of novel biologics in development across many therapeutic classes, alongside state-of-the-art biologics manufacturing capabilities and a broad intellectual property portfolio.

Katja buhrerRichard chinHc wainwright global life sciences conferenceKindred biosciences incKindred biosciencesBarclays global healthcare conferenceGlobal life sciences conferenceChief executive officerVirtual trackரிச்சர்ட் கன்னம்ஹ்ஸீ வேந்‌ரைட் உலகளாவிய வாழ்க்கை அறிவியல் மாநாடுகிஂட்ரிட் உயிர் அறிவியல் இன்க்கிஂட்ரிட் உயிர் அறிவியல்பார்க்லேஸ் உலகளாவிய சுகாதாரம் மாநாடுஉலகளாவிய வாழ்க்கை அறிவியல் மாநாடுதலைமை நிர்வாகி அதிகாரி